Biotech Values

[rkrw]

Bear in mind Copaxone's patents expire in May 2014, now less then 3 years away. An earlier launch is obviously better given a more competitive MS market, but even if Teva were to fend off the patent challenge, it's coming not too far in front of the end to their patent life. To my eye getting actual FDA approval is a lot more important than the patent challenge, cart before the horse.